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Abstract:
The role of haploidentical hematopoietic cell transplantation (HCT) using post-transplant
cyclophosphamide (PTCy) for acute lymphoblastic leukemia (ALL) is being defined. We performed a
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in remission. The primary objective was to compare overall survival (OS) between haploidentical HCT
using PTCy and HLA-matched sibling donor (MSD), 8/8 HLA-matched unrelated donor (MUD) , 7/8 HLA-matched
UD, or umbilical cord blood (UCB) HCT. Comparing haploidentical to MSD HCT, OS, leukemia-free survival
(LFS), non-relapse mortality (NRM), relapse, and acute graft-versus-host disease (aGVHD) were not
different but chronic GVHD (cGVHD) was higher with MSD HCT. Compared to MUD HCT, OS, LFS, and relapse
were not different but MUD HCT had increased NRM (HR 1.42, P=0.02), grade 3-4 aGVHD (HR 1.59, P=0.005),
and cGVHD. Compared to 7/8 UD HCT, LFS and relapse were not different, but 7/8 UD HCT had worse OS (HR
1.38, P=0.01) and increased NRM (HR 2.13, P=<0.001), grade 3-4 aGVHD (HR 1.86, P=0.003), and cGVHD (HR
1.72, P=<0.001). Compared to UCB HCT, late OS , late LFS, relapse, and cGVHD were not different but UCB
HCT had worse early OS ({less than or equal to}18 months, HR 1.93, P<0.001), worse early LFS (HR 1.40,
P=0.007) and increased incidences of NRM (HR 2.08, P<0.001) and grade 3-4 aGVHD (HR 1.97, P<0.001).
Haploidentical HCT using PTCy showed no difference in survival but less GVHD compared to traditional MSD
and MUD HCT and is the preferred alternative donor HCT option for adults with ALL in CR.
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Key points  
 
Haploidentical hematopoietic cell transplantation is the preferred alternate donor 
approach for adults with acute lymphoblastic leukemia. 
 
Haploidentical transplantation had similar survival compared to fully HLA-matched 











The role of haploidentical hematopoietic cell transplantation (HCT) using post-transplant 
cyclophosphamide (PTCy) for acute lymphoblastic leukemia (ALL) is being defined. We 
performed a retrospective, multivariate analysis comparing outcomes of HCT 
approaches by donor for adults with ALL in remission.  The primary objective was to 
compare overall survival (OS) between haploidentical HCT using PTCy and HLA-matched 
sibling donor (MSD), 8/8 HLA-matched unrelated donor (MUD) , 7/8 HLA-matched UD, 
or umbilical cord blood (UCB) HCT. Comparing haploidentical to MSD HCT, OS, leukemia-
free survival (LFS), non-relapse mortality (NRM), relapse, and acute graft-versus-host 
disease (aGVHD) were not different but chronic GVHD (cGVHD) was higher with MSD 
HCT. Compared to MUD HCT, OS, LFS, and relapse were not different but MUD HCT had 
increased NRM (HR 1.42, P=0.02), grade 3-4 aGVHD (HR 1.59, P=0.005), and cGVHD.  
Compared to 7/8 UD HCT, LFS and relapse were not different, but 7/8 UD HCT had 
worse OS (HR 1.38, P=0.01) and increased NRM (HR 2.13, P=<0.001), grade 3-4 aGVHD 
(HR 1.86, P=0.003), and cGVHD (HR 1.72, P=<0.001). Compared to UCB HCT, late OS , 
late LFS, relapse, and cGVHD were not different but UCB HCT had worse early OS (≤18 
months, HR 1.93, P<0.001), worse early LFS (HR 1.40, P=0.007) and increased incidences 
of NRM (HR 2.08, P<0.001) and grade 3-4 aGVHD (HR 1.97, P<0.001). Haploidentical HCT 
using PTCy showed no difference in survival but less GVHD compared to traditional MSD 













Allogeneic hematopoietic cell transplantation (HCT) is a curative therapy for acute 
lymphoblastic leukemia (ALL) and has been shown to be superior to intensive 
chemotherapy alone in some studies1,2. The MRC UK ALL XII/E2993 study compared an 
adult chemotherapy backbone or chemotherapy followed by myeloablative autologous 
HCT to myeloablative allogeneic HCT in patients with ALL aged 15-59 years.  An overall 
survival (OS) benefit was seen in standard-risk ALL patients with a donor primarily due 
to higher rate of relapse in the no donor group that combined chemotherapy and 
autologous HCT groups1. A meta-analysis of 13 trials comparing allogeneic HCT to 
chemotherapy with or without autologous HCT concluded that the benefit of allogeneic 
HCT for ALL in first complete remission (CR)  was limited to patients under the age of 
353. Recent studies have also shown that allogeneic HCT in first CR yields similar 
outcomes to pediatric-inspired chemotherapy in MRD-negative patients but improves 
outcomes for patients with MRD-positive disease4.  For these MRD-positive patients, 
who benefit most from allogeneic HCT in first CR, donor availability is especially 
important as haploidentical HCT or umbilical cord blood (UCB) HCT may shorten the 
time to allogeneic HCT and promote the higher cure rates observed with traditional fully 
HLA-matched donor allogeneic HCT.  
 
The optimal donor for allogeneic HCT based on existing data appears to be a matched 









unavailable. A recently published CIBMTR study compared outcomes of traditional 
donor (MSD or MUD) HCT and 7/8 HLA-matched UD HCT for adults with ALL. Compared 
with MSD HCT, MUD HCT yielded similar survival outcomes whereas the alternative 7/8 
HLA-matched UD HCT had inferior survival5. For patients without a related or unrelated 
donor, haploidentical HCT using post-transplant cyclophosphamide (PTCy) for graft-
versus-host disease (GVHD) prophylaxis is now a common alternative transplant 
modality with demonstrated efficacy in ALL6-8. In addition, 7/8 HLA-matched UD, despite 
inferior outcomes to MSD and MUD HCT, and UCB HCT remain alternative graft sources 
for adult patients with ALL without a fully HLA-matched donor.  
 
Although there are expanding comparative data supporting the use of haploidentical 
HCT as a reasonable alternative to traditional MSD and MUD allogeneic HCT for AML9-13, 
for ALL comparative data is more limited.  Recent retrospective, comparative studies 
using the European Society for Blood and Marrow Transplantation (EBMT) registry have 
found no differences in outcomes between haploidentical HCT using PTCy and MSD, 
MUD, and mismatched UD (MMUD) HCT14,15.  Comparison of results of parallel Phase 2 
studies of reduced-intensity conditioning haploidentical HCT using PTCy and UCB HCT in 
lymphoma and acute leukemia was addressed in the BMT-CTN 1101 study. The study 
found no difference in the primary endpoint of progression-free survival at 2 years but 
found increased non-relapse mortality (NRM) and decreased overall survival (OS) with 
UCB HCT compared to haploidentical HCT with PTCy16. Taken together, prior studies 









MSD, MUD, or MMUD HCT and a superior alternative donor approach among 
haploidentical HCT with PTCy, 7/8 HLA-matched UD HCT, and UCB HCT for adult ALL 
specifically has not been established.  
 
This retrospective, multivariate study was designed to compare OS, leukemia-free 
survival (LFS), relapse, and NRM between adult ALL patients undergoing post-remission 
therapy with haploidentical HCT using post-transplant cyclophosphamide (PTCy) 
compared to MSD HCT, MUD HCT, 7/8-HLA matched UD HCT, or umbilical cord blood 
(UCB) HCT. We hypothesized that haploidentical HCT using PTCy would result in similar 
OS compared with MSD, MUD, and UCB HCT and superior OS compared with 7/8 HLA-
matched UD HCT in adults with ALL undergoing first allogeneic HCT in CR. Results from 
this study further define the role of haploidentical HCT for ALL in first or subsequent 















All patient data were generated from the Center for International Blood and Marrow 
Transplant Research (CIBMTR) patient registry. Eligible patients were 18 years of age or 
older with a diagnosis of ALL in first, second, or third or greater CR undergoing first 
allogeneic HCT from 2013 through 2017.  Patients must have had an allogeneic HCT 
from a haploidentical, HLA-matched sibling, 8/8 HLA-matched unrelated, 7/8 HLA-
matched unrelated, or cord blood donor17. Patients undergoing haploidentical HCT not 
employing PTCy-based GVHD prophylaxis were excluded as were those receiving ex vivo 
T-cell depletion or CD34 selection.  Also excluded were patients without consent to 
research, from embargoed centers, with no follow-up forms, alive with <3 months of 
follow up, or receiving infrequently observed conditioning regimens. Minimal residual 
disease (MRD) testing methods and positivity was as reported from CIBMTR sites. MRD 
testing methods included flow cytometry (75%), molecular methods (76%), and 
cytogenetics (62%) with 74% of patients being evaluated with more than one method. 
Data on MRD testing methods was missing for 7% of patients. The study was approved 











The primary objective was to compare OS after HCT between the following donor-
transplant  groups: (1) haploidentical HCT using PTCy, (2) MSD HCT, (3) MUD HCT, (4) 
7/8 HLA-matched-UD HCT, and (5) UCB HCT.  Secondary objectives included comparing 
the LFS, relapse, NRM, Grade 2-4 and Grade 3-4 acute GVHD (aGVHD) rates 18, and 
chronic GVHD (cGVHD) rates19 between the groups. We also performed two planned 
sensitivity analyses restricting the analysis to (1) myeloablative conditioning20 with 
peripheral blood as hematopoietic stem cell source for non-cord blood donor types and 




This was a retrospective, five cohort, comparative study from the CIBMTR. Patient, 
disease and transplant-related factors were compared between the 5 transplant groups 
using Chi-square test for categorical and Mann-Whitney test for continuous variables. 
The outcomes that were analyzed were OS, LFS, cumulative incidence of relapse, 
cumulative incidence of NRM, rate of aGVHD, and rate of cGVHD. OS was the time from 
transplant to death from any cause with surviving patients censored at last time 
reported alive.  LFS was the time to leukemia relapse or death from any cause with 
surviving patients censored at last time reported alive and leukemia-free. NRM was 
summarized by the cumulative incidence estimate of death in CR with relapse as a 
competing risk. Relapse was summarized by the cumulative incidence estimate with 









calculated using the Kaplan-Meier estimator. Cumulative incidence curves were made to 
present relapse and NRM with time to relapse and time to NRM as competing risks.   
 
To adjust for the differences in baseline characteristics, Cox proportional hazards 
regression were used to compare the main treatment groups. First, variables to be 
considered in the multivariate models were selected. Variables considered were donor 
type, recipient age, Karnofsky performance status, gender, HCT-CI score21, race, ALL 
lineage, Philadelphia chromosome/BCR-ABL1 status, cytogenetic risk, remission status, 
MRD status for CR1, time from diagnosis to HCT for CR1, conditioning intensity, 
donor/recipient sex match, donor/recipient CMV serostatus, year of transplant, and 
transplant center. The assumption of proportional hazards for each factor in the Cox 
model was tested using time-dependent covariates. When the test indicated differential 
effects over time (non-proportional hazards), models were constructed breaking the 
post-transplant time course into two periods, using the maximized partial likelihood 
method to find the most appropriate breakpoint. The proportionality assumptions were 
further tested.  A backward stepwise model selection approach was used to identify all 
significant risk factors. Each step of model building contained the main effect for 
treatment groups. Factors which were significant at a 5% level were kept in the final 
model. The potential interactions between main effect and all significant risk factors 
were tested. Adjusted probabilities of LFS and OS, and adjusted cumulative incidence 
estimates were generated from the final regression models stratified on treatment and 









function.  These adjusted probabilities estimate likelihood of outcomes in populations 
with similar prognostic factors. With haploidentical HCT using PTCy as the baseline 
comparison group (independent testing, no multiple testing considered, no differences 
in patient characteristics adjusted, assuming all subjects had at least 2-year follow-up), 
power test for 2-year OS probability based on two-sided test with significance level of 
5%: haploidentical HCT using PTCy vs MSD HCT, 80% power to detect at least difference 
of 8%; haploidentical HCT using PTCy vs MUD HCT, 80% power to detect at least 
difference of 8%; haploidentical HCT using PTCy vs 7/8 HLA-matched UD HCT,  80% 
power to detect at least difference of 11%; haploidentical HCT using PTCy vs UCB HCT, 






Between 2013 and 2017, a total of 4201 patients in 5 HCT cohorts were eligible: 393 
haploidentical HCT using PTCy, 1627 MSD HCT, 1646 MUD HCT, 230 7/8 HLA-matched 
UD HCT, and 305 UCB HCT. Cohorts were well matched for age, sex, Karnofsky 
performance status, HCT-CI, immunophenotype, cytogenetic risk, Philadelphia 
chromosome/BCR-ABL1 status, disease status, MRD status at transplantation, and 
recipient CMV serostatus. Notable differences between groups included race, time from 









non-cord (peripheral blood or bone marrow), GVHD prophylaxis modality, and the use 
of in vivo T-cell depletion. PTCy-based GVHD prophylaxis was used in 5% of MSD HCT, 
4% of MUD HCT, and 13% of 7/8 HLA-matched UD HCT. Compared to other groups, 
haploidentical HCT using PTCy had the lowest percentage of non-Hispanic white patients 
(43% vs. 49-74%), was more likely to use reduced-intensity conditioning (42% vs 17-
25%) and was more likely to use bone marrow as the graft source (41% vs. 14-29%). See 
Table 1 for details.  
 
Overall and Leukemia-free Survival 
 
In multivariate analysis, compared to haploidentical HCT, MSD HCT and MUD HCT had 
similar OS  (HR 1.13, P=0.18 and HR 1.17, P=0.11, respectively) and LFS (HR 1.03, P=0.71 
and HR 1.03, P=0.73 respectively). In contrast, 7/8 HLA-matched UD HCT had inferior OS 
and similar LFS when compared to haploidentical HCT (OS, HR 1.38, P=0.01; LFS, HR 
1.21, P=0.12).  UCB HCT had inferior OS prior to 18 months (HR 1.93, P=<0.001) and 
similar OS after 18 months (HR 0.68, P=0.19) when compared to haploidentical HCT. In 
addition, LFS prior to 18 months was inferior with UCB HCT (HR 1.40, P=0.007) and 
similar after 18 months (HR 0.58, P=0.08). Other multivariate factors associated with 
decreased OS included HCT in CR2+, older age, female donor to male recipient, Ph/BCR-
ABL1 negativity, and CMV-seronegative donor to CMV-seropositive recipient for MSD 
HCT vs. haploidentical HCT; CR2+, older age, non-Asian race, HCT-CI 3+, and Ph/BCR-









vs. haploidentical HCT; and CR2+ and myeloablative chemotherapy (vs. myeloablative 
TBI) for UCB HCT vs. haploidentical HCT. Multivariate survival outcomes are summarized 
in Tables 2-5 and Figure 1. Univariate outcomes are summarized in Supplemental Table 
3. 
 
Relapse and Non-relapse Mortality 
 
In multivariate analysis, MSD HCT had similar relapse (HR 0.99, P=0.93) and NRM (HR 
1.06, P=0.66) compared to haploidentical HCT. Compared to haploidentical HCT, relapse 
was not significantly different with MUD HCT (HR 0.83, P=0.09), 7/8 HLA-matched UD 
HCT (HR 0.81, P=0.22), or UCB HCT (HR 0.83, P=0.23). NRM, however, was significantly 
higher with MUD HCT (HR 1.42, P=0.02), 7/8 HLA-matched UD HCT (HR 2.13, P=<0.001), 
or UCB HCT (HR 2.08, P=<0.001) compared to haploidentical HCT. Notably, 
myeloablative conditioning using total body irradiation significantly reduced the risk of 
relapse across all donor HCT cohorts. Multivariate relapse and NRM analyses are 
summarized in Tables 2-5 and Figure 1. Univariate analyses are summarized in 













Multivariate analysis revealed either reduced or similar rates of severe acute GVHD and 
chronic GVHD with haploidentical HCT using PTCy relative to other HCT cohorts. 
Compared to haploidentical HCT, MSD HCT had similar cumulative incidences of grade 
2-4 and grade 3-4 acute GVHD (HR 0.92, P=0.40 and HR 1.09, P=0.59, respectively) but 
increased cumulative incidence of chronic GVHD (HR 2.59, P<0.001 for female/male 
donor/recipient sex match; HR 1.37, P=0.003 for other donor/recipient sex match). MUD 
HCT had a similar cumulative incidence of grade 2-4 acute GVHD (HR 1.17, P=0.09), an 
increased cumulative incidence of grade 3-4 acute GVHD (HR 1.59, P=0.005), and an 
increased cumulative incidence of chronic GVHD (HR 1.38, P=0.001).  7/8 HLA-matched 
UD HCT had an increased cumulative incidence of Grade 2-4 acute GVHD (HR 1.33, 
P=0.04), Grade 3-4 acute GVHD (HR 1.86, P=0.003), and chronic GVHD (HR 1.72, 
P<0.001). UCB HCT was associated with an increased cumulative incidence of grade 2-4 
and grade 3-4 acute GVHD (HR 1.83, P<0.001 and HR 1.97, P<0.001, respectively) with a 
similar cumulative incidence of chronic GVHD (HR 1.13, P=0.38). Multivariate GVHD 
analyses are summarized in Tables 2-5. 
 
Causes of Death 
 
Death from acute lymphoblastic leukemia was more common with haploidentical HCT 
(48%) and HLA-identical sibling HCT (52%) relative to other HCT cohorts (31-38%). Death 
from graft-versus-host disease accounted for 5% of deaths after haploidentical HCT 









observed comparing haploidentical HCT (21%) to other HCT cohorts (17-23%). Other 




To address two potential sources of bias, we performed two sensitivity analyses for OS, 
LFS, relapse, and NRM restricting the study population to either the most common 
modalities of myeloablative conditioning with peripheral blood as hematopoietic stem 
cell source or to United States centers for better completion of follow up at 2 years. 
When restricted to myeloablative conditioning and peripheral blood stem cell source, 
outcomes were similar to the full population except decreased overall survival with 7/8 
HLA-matched UD compared to haploidentical HCT was no longer statistically significant 
(HR 1.39, P=0.07; Supplemental Tables 1, 4, 6-9, Supplemental Figures 1-4). When 
restricted to United States centers only, outcomes were also similar except with a 
decreased risk of relapse (HR 0.76, P=0.02) but inferior overall survival (HR 1.23, 95% CI 
1.00-1.50, P=0.05) with MUD compared to haploidentical HCT See Supplemental Tables 




Haploidentical HCT is a growing allogeneic HCT modality for ALL that has expanded 









especially those of mixed race or ethnicity. The choice of alternative donors for 
allogeneic HCT in ALL is an area of ongoing research, debate and clinical interest. In 
addition, the relative benefits of haploidentical HCT compared to traditional MSDs and 
MUDs is just being defined. In this study, we demonstrated that haploidentical HCT 
using PTCy resulted in similar OS  to traditional MSDs and MUDs allogeneic HCT but with 
less GVHD.  In addition, we found superior OS compared to alternative 7/8 HLA-matched 
UD and UCB HCT. The superior survival seen with haploidentical HCT using PTCy 
compared with 7/8 HLA-matched UD HCT and UCB HCT was likely due to reduced NRM 
related to reduced GVHD with haploidentical HCT. Notably, rates of infection were 
similar among the 5 cohorts suggesting that delayed immune reconstitution with 
haploidentical HCT in the adult ALL population did not translate into increased infection-
related mortality.  
 
Prior smaller retrospective studies comparing haploidentical HCT to MSD, MUD, and 
MMUD HCT found no differences in DFS, relapse, NRM, aGVHD or cGVHD. Recently, 
Shem-Tov et al. performed a retrospective multi-institution comparison of 136 ALL 
patients undergoing haploidentical HCT to 809 ALL patients getting MUD HCT and 289 
ALL patients getting 9/10 HLA-matched UD HCT. This smaller study found no differences 
in OS, LFS, relapse, NRM, aGVHD, or cGVHD between the groups.14 Similarly, a larger 
study comparing 487 haploidentical HCTs to 974 MUD HCTs for ALL found no difference 
in any outcome including aGVHD and cGVHD.15 Our study expands on and contrasts 









major outcomes between haploidentical HCT using PTCy to all other major donor 
sources. This study helps clarify the role of haploidentical HCT in adult ALL and expands 
our knowledge of the expected benefits of haploidentical HCT relative to other donor 
HCT approaches. Importantly, our study supports haploidentical HCT with PTCy as the 
preferred HCT approach for patients lacking an MSD or MUD donor.   
 
Similar to prior studies22-25, we found that myeloablative conditioning using TBI 
compared with myeloablative chemotherapy or reduced-intensity/non-myeloablative 
conditioning significantly reduced the risk of relapse and improved LFS across all donor 
HCT cohorts. The recently published Phase III FORUM study randomized 417 children 
and young adults ages 4-21 years with ALL to either myeloablative TBI-based or 
myeloablative chemotherapy-based conditioning prior to MSD, MUD, or MMUD 
allogeneic HCT. Patients in the TBI arm had improved OS, improved event-free survival, 
less relapse, and improved NRM23. In adults with ALL, a retrospective EBMT registry 
study comparing TBI-based to chemotherapy-myeloablative conditioning for MSD< 
MUD, or MMUD allogeneic HCT found better OS, LFS, and relapse incidence with TBI-
based conditioning24, although the OS benefit in adults has not been seen across all 
retrospective studies22,25. In this study, the benefit of myeloablative conditioning using 
total body irradiation on reducing relapse only improved OS in haploidentical HCT and 
UCB HCT comparison, suggesting these modalities may derive more benefit from TBI. 
Overall, our study supports current recommendations26 for the use of myeloablative TBI 









or improved OS, but further study is warranted on optimal conditioning regimens across 
donor HCT types for adult ALL.  
 
The primary reason for decreased NRM with haploidentical HCT compared to MUD HCT, 
7/8 MMUD HCT, and UCB HCT appears to be significantly decreased rates of severe 
acute and chronic GVHD with haploidentical HCT using PTCy. Death from GVHD was 
substantially higher in the non-haploidentical HCT cohorts and reduced quality of life 
from GVHD-related complications, although not assessed in this study, with other donor 
sources may be an additional reason to pursue haploidentical HCT with PTCy in the ALL 
population. Based on its success in haploidentical HCT, PTCy GVHD prophylaxis is being 
studied in MSD, MUD, and MMUD HCT. Existing studies evaluating alternative GVHD 
prophylaxis with PTCy for MSD and UD HCT27-30 have consistently found low rates of 
cGVHD and these approaches may produce similar relative benefits seen with 
haploidentical HCT in this study for reducing GVHD and NRM. However, the impact of 
these approaches on relapse in the setting of fully HLA-matched donor HCT will need to 
be closely evaluated. 
 
Although hazard ratios for relapse favored non-haploidentical HCT modalities except 
HLA-identical sibling (HRs 0.81-0.83), this finding was not statistically significant and did 
not lead to inferior OS or LFS with haploidentical HCT using PTCy. When restricted to 
United Stated sites only, relapse was significantly higher with haploidentical HCT using 









that relapse may be higher in some settings with haploidentical HCT although in the 
same comparison haploidentical HCT showed significantly better OS due to substantially 
lower NRM.  A larger future study and longer follow up are needed to evaluate if the 
large and significant reduction in acute and chronic GVHD and death from GVHD with 
haploidentical HCT may be associated with a small increased risk of relapse after HCT. 
Non-severe acute and chronic GVHD have been previously associated with reduced 
relapse31 and this study suggests that reducing GVHD with haploidentical HCT may 
impact relapse. Consistent with this, MSD HCT and haploidentical HCT had similar rates 
of acute GVHD and nearly identical risk of relapse (HR 0.99).  
 
A strength of this study is the large number patients and international centers allowing  
generalization the results, especially to United States centers. In addition, the large 
sample size in each cohort allowed adequate power to detect meaningful differences in 
outcomes between the HCT approaches. One limitation of this study is that it is 
retrospective and a prospective randomized study to better control for numerous 
variables would be needed to confirm our findings and address some limitations. For 
instance, the impact on outcomes from large centers favoring certain donor HCT 
modalities could influence the results. Another limitation is lack of standardized testing 
and definitions for MRD in data collected from sites. We found no differences in overall 
survival based on the CIBMTR definitions of MRD prior to HCT in contrast to a recent 
EBMT registry report24. However, well-defined MRD positivity prior to allogeneic HCT 









after allogeneic HCT for ALL32-40.  Reasons for our findings could be heterogeneity in 
testing,  definitions of MRD used at different CIBMTR sites, and possibly a lack of 
sensitivity of MRD for predicting outcomes in a real-world setting. Another limitation of 
our study was an inability  to evaluate the impact of central nervous system and 
extramedullary ALL on outcomes as this data was not reported from centers. Follow up 
for this study was also relatively short given that haploidentical HCT has only come into 
widespread use in the last 5 years. Lastly, our analysis is restricted to patients 
undergoing haploidentical HCT employing PTCy and our conclusions may not extend to 
alternate haploidentical HCT approaches. Approaches utilizing in vivo T-cell depletion or 
in vitro T-cell depletion/CD34+ cell selection have shown promising outcomes in ALL 
that appear comparable or possibly superior to MSD and MUD allogeneic HCT.41-48 High-
quality comparative studies are needed that compare well-matched populations 
undergoing T-cell replete haploidentical HCT using PTCy with approaches using in vivo T-
cell depletion or in vitro T-cell depletion/CD34+ cell selection.  
 
Our findings support haploidentical HCT using PTCy as the preferred alternative donor 
HCT for ALL given the superior OS seen relative to 7/8 HLA-matched UD and UCB HCT. 
Our data also suggest that OS is not different with haploidentical HCT using PTCy 
compared with traditional MSD and MUD HCT, but with a reduced risk of GVHD. 
Although longer follow up and confirmatory studies are needed, from this analysis 
haploidentical HCT appears to be an acceptable HCT option for all adult patients with 









causes of failure of haploidentical HCT uncovered in this study, future studies aiming to 
prevent relapse and reduce infectious death may further improve outcomes after 
haploidentical HCT.   Future studies with longer follow-up will also be needed to 
definitively establish the role of haploidentical HCT using PTCy at different stages of ALL 
remission, particularly in the era of effective salvage treatments such as bispecific T-cell 
engagers, antibody-drug conjugates, and cellular therapies. 
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Figure 1. Overall survival, leukemia-free survival, cumulative incidence or relapse, and 
cumulative incidence of non-relapse mortality comparing haploidentical hematopoietic 
cell transplantation (HCT) with post-transplant cyclophosphamide to matched sibling, 









Table 1. Patient characteristics 










      
Number of patients 393 1627 1646 230 305 
Number of centers 92 206 181 90 79 
Median follow-up, months (range)  24 (3-67) 26 (3-72) 35 (3-74) 35 (3-64) 35 (3-64) 
Recipient age, median, years (range) 41 (18-74) 42 (18-75) 43 (18-77) 38 (18-70) 37 (18-70) 
Karnofsky performance status score      
≥90% 233 (59) 1046 (64) 995 (60) 163 (71) 196 (64) 
<90% 152 (39) 542 (33) 629 (38) 65 (28) 107 (35) 
Missing 8 (2) 39 (2) 22 (1) 2 (<1) 2 (<1) 
Recipient gender      
Male 214 (54) 969 (60) 976 (59) 134 (58) 176 (58) 
HCT-CI score      
0 81 (21) 592 (36) 405 (25) 53 (23) 89 (29) 
1 57 (15) 221 (14) 224 (14) 35 (15) 42 (14) 
2 61 (16) 228 (14) 266 (16) 37 (16) 46 (15) 
3+ 194 (49) 552 (34) 745 (45) 104 (45) 125 (41) 
Missing 0 34 (2) 6 (<1) 1 (<1) 3 (<1) 
Racea      
Hispanic white 87 (22) 246 (15) 136 (8) 42 (18) 64 (21) 
Non-Hispanic white 170 (43) 846 (52) 1226 (74) 113 (49) 150 (49) 
Black 59 (15) 74 (5) 53 (3) 19 (8) 27 (9) 
Asian 22 (6) 111 (7) 64 (4) 10 (4) 22 (7) 
Other/Not specified 55 (14) 350 (22) 167 (10) 46 (20) 42 (14) 
Immunophenotype      
T-cell 25 (6) 201 (12) 186 (11) 27 (12) 36 (12) 
B-cell 330 (84) 1316 (81) 1319 (80) 185 (80) 246 (81) 
Not specified 38 (10) 110 (7) 141 (9) 18 (8) 23 (8) 
Cytogenetic risk scoreb      
Normal 91 (23) 320 (20) 335 (20) 52 (23) 63 (21) 
Poor 222 (56) 750 (46) 855 (52) 101 (44) 154 (50) 
Missing/Not tested/Other  80 (21) 557 (34) 456 (28) 77 (33) 88 (29) 
Philadelphia chromosome/BCR-ABL1 
status 
     
Yes 152 (46) 562 (43) 614 (47) 80 (43) 122 (50) 
Remission status      
CR1- MRD positive 112 (28) 513 (32) 509 (31) 58 (25) 78 (26) 
CR1- MRD negative 143 (36) 644 (40) 697 (42) 85 (37) 124 (41) 
CR1- MRD missing 14 (4) 145 (9) 59 (4) 6 (3) 10 (3) 
CR2 105 (27) 296 (18) 334 (20) 62 (27) 74 (24) 
≥ CR3 19 (5) 29 (2) 47 (3) 19 (8) 19 (6) 
Time from diagnosis to HCT (CR1-only)      
0-5 months 130 (48) 842 (65) 744 (59) 56 (38) 93 (44) 
6-11 months 115 (43) 388 (30) 463 (37) 81 (54) 102 (48) 
≥ 12 months 24 (9) 72 (6) 58 (5) 12 (8) 17 (8) 
Conditioning regimen        
MAC, TBI-based 163 (41) 984 (60) 950 (58) 139 (60) 217 (71) 









RIC/NMA 167 (42) 316 (19) 383 (23) 39 (17) 76 (25) 
Missing 0 4 (<1) 1 (<1) 1 (<1) 1 (<1) 
Donor/recipient gender      
F-M  82 (21) 415 (26) 244 (15) 42 (18) 161 (53) 
Other  311 (79) 1212 (74) 1396 (85) 188 (82) 137 (45) 
Missing 0 0 6 (<1) 0 7 (2) 
Donor/recipient CMV serostatus      
+/+ 206 (52) 859 (53) 506 (31) 90 (39) 0 
+/- 31 (8) 144 (9) 197 (12) 25 (11) 0 
-/+ 83 (21) 287 (18) 553 (34) 64 (28) 0 
-/- 72 (18) 306 (19) 382 (23) 50 (22) 0 
UCB – Recipient + 0 0 0 0 200 (66) 
UCB – Recipient - 0 0 0 0 100 (33) 
Missing 1 (<1) 31 (2) 8 (<1) 1 (<1) 5 (2) 
Donor age, median, years (range) 35 (10-74) 41 (9-75) 28 (18-60) 31 (19-60) Not 
applicable 
Graft source      
Bone marrow 160 (41) 230 (14) 316 (19) 67 (29) - 
Peripheral blood 233 (59) 1397 (86) 1330 (81) 163 (71) - 
GVHD prophylaxis      
CNI + MTX ± others 0 1107 (68) 1165 (71) 162 (70) 7 (2) 
CNI + MMF ± others 0 236 (15) 191 (12) 18 (8) 265 (87) 
CNI + others 0 118 (7) 141 (9) 13 (6) 6 (2) 
CNI alone 0 66 (4) 58 (4) 5 (2) 14 (5) 
PTCy + CNI ± MMF 393 75 (5) 73 (4) 29 (13) 2 (<1) 
Other prophylaxis 0 17 (1) 13 (<1) 2 (<1) 10 (3) 
Missing 0 8 (<1) 5 (<1) 1 (<1) 1 (<1) 
In vivo T-cell depletion       
Anti-thymocyte globulin  5 (1) 76 (5) 561 (34) 116 (50) 39 (13) 
Alemtuzumab  0 33 (2) 62 (4) 6 (3) 0 
None 388 (99) 1505 (93) 1010 (61) 105 (46) 265 (87) 
Missing 0 13 (<1) 13 (<1) 3 (1) 1 (<1) 
      
Abbreviations: HLA, human leukocyte antigen; MUD, matched unrelated donor; HCT-CI, hematopoietic cell transplant comorbidity 
index; CR, complete remission; MRD, minimal residual disease; MAC, myeloablative conditioning; TBI, total body irradiation; RIC, 
reduced-intensity conditioning; NMA, non-myeloablative; F, female; M, male; CMV, cytomegalovirus; UCB, umbilical cord blood; 
CNI, calcineurin inhibitor; MTX, methotrexate; MMF, mycophenolate mofetil; PTCy, post-transplant cyclophosphamide 
 
a
Other/ not specified: Native American (n=30), Pacific Islander (n=20), Non-resident of the US (n=291), not specified (n= 156), 
Hispanic – excluding white Hispanic (n= 213) 
b
CIBMTR cytogenetics criteria definition: Poor: Ph+/t(9:22)/BCR-ABL1, t(4:11), 11q23/MLL/KMT2A, hypodiploid (<45), t(8:14), 
complex(≥ 3 abnormalities), iAMP21; Normal: without any abnormality;  Other: abnormality count 1 or 2 abnormalities.  
c
Donor age is not reported for cord bloods. 
d














Table 2. Multivariate analysis for HLA-matched sibling donor (MSD) HCT vs. 
haploidentical HCT, 2013-2017 
 
Covariate N HR (95% CI) p-value 
    
Overall survival     
    Main effect    
 Haploidentical HCT  393 Reference  
 MSD HCT 1627 1.13 (0.94-1.36) 0.18 
    Remission status    
 CR1 1571 Reference  
 CR2+ 449 1.86 (1.58-2.19) < 0.001 
     Age (years)   < 0.001 
 18-29 572 Reference  
 30-39 367 0.97 (0.77-1.22) 0.78 
 40-49 432 1.30 (1.05-1.60) 0.02 
 50-59 417 1.49 (1.21-1.85) < 0.001 
 60-69 232 2.07 (1.63-2.63) < 0.001 
    Donor/recipient sex match    
 Other than F/M 1523 Reference  
 F/M 497 1.29 (1.10-1.51) 0.002 
    Ph chromosome/BCR-ABL1 status   0.007 
 Negative 932 Reference  
 Positive 714 0.78 (0.66-0.92) 0.003 
 T-ALL/ Unspecified subtype 374 1.02 (0.84-1.24) 0.83 
    D/R CMV serostatus   0.02 
 +/+ 1065 Reference  
 +/- 175 0.81 (0.62-1.05) 0.11 
 -/+ 370 0.76 (0.62-0.93) 0.007 
 -/- 378 0.84 (0.69-1.01) 0.07 
Leukemia-free survival    
    Main effect    
 Haploidentical HCT 381 Reference  
 MSD HCT 1583 1.03 (0.88-1.22) 0.71 
    Disease status    
 CR1 1528 Reference  
 CR2+ 436 1.93 (1.67-2.23) < 0.001 
    Conditioning regimen    
 MAC-TBI 1116 Reference  
 MAC-Chemotherapy 376 1.35 (1.15-1.60) < 0.001 
 RIC/NMA 470 1.50 (1.28-1.76) < 0.001 
Non-relapse mortality    









Covariate N HR (95% CI) p-value 
 Haploidentical HCT 381 Reference  
 MSD HCT 1583 1.06 (0.81-1.41) 0.66 
    Remission status    
 CR1 1528 Reference  
 CR2+ 436 1.52 (1.17-1.98) 0.002 
    Age (years)   < 0.001 
 18-29 553 Reference  
 30-39 353 0.66 (0.44-0.99) 0.04 
 40-49 422 1.19 (0.86-1.65) 0.28 
 50-59 411 1.59 (1.17-2.16) 0.003 
 60-69 225 2.10 (1.49-2.96) < 0.001 
    D/R sex match    
 Other than F/M 1479 Reference  
 F/M 485 1.54 (1.22-1.94) < 0.001 
Relapse    
    Main effect    
 Haploidentical HCT 381 Reference  
 MSD HCT  1583 0.99 (0.81-1.21) 0.93 
    Remission status    
 CR1 1528 Reference  
 CR2+ 436 2.25 (1.89-2.68) < 0.001 
    Conditioning regimen    
 MAC-TBI 1116 Reference  
 MAC-Chemotherapy 376 1.40 (1.14-1.72) 0.001 
 RIC/NMA 470 1.53 (1.26-1.87) < 0.001 
Acute GVHD, Grade 2-4    
    Main effect    
 Haploidentical HCT 376 Reference  
 MSD HCT 1545 0.92 (0.77-1.11) 0.40 
Acute GVHD, Grade 3-4    
    Main effect    
 Haploidentical HCT 376 Reference  
 MSD HCT 1545 1.09 (0.79-1.50) 0.59 
Chronic GVHD    
    MSD vs. haploidentical HCT for D/R sex match = other  1.37 (1.12-1.69) 0.003 
    MSD vs. haploidentical HCT for D/R sex match = F/M  2.59 (1.68-3.99) < 0.001 
    Age (years)   0.002 
 18-29 563 Reference  
 30-39 361 1.13 (0.93-1.37) 0.24 
 40-49 428 1.37 (1.14-1.64) < 0.001 
 50-59 413 1.17 (0.95-1.43) 0.14 
 60-69 228 1.57 (1.21-2.03) < 0.001 
    Race    









Covariate N HR (95% CI) p-value 
 White non-Hispanic 1006 0.75 (0.63-0.89) 0.001 
 Black 132 0.93 (0.70-1.23) 0.61 
 Asian 130 0.79 (0.59-1.07) 0.13 
 Other/not specified 392 0.66 (0.53-0.82) < 0.001 
    D/R sex match    
 Other than F/M 1501 Reference  
 F/M 492 0.73 (0.47-1.14) 0.17 
    Conditioning regimen    
 MAC-TBI 1132 Reference  
 MAC-Chemotherapy 380 0.94 (0.79-1.11) 0.46 
 RIC/NMA 478 0.74 (0.61-0.90) 0.002 
Abbreviations: HLA, human leukocyte antigen; HCT, hematopoietic cell transplantation; N, number; HR, hazard ratio; CI, 
confidence interval; CR, complete remission; F, female; M, male; Ph, Philadelphia; BCR-ABL, breakpoint cluster region-Abelson 
murine leukemia; ALL, acute lymphoblastic leukemia; D, donor; R, recipient; CMV, cytomegalovirus; MAC, myeloablative; TBI, 











Table 3. Multivariate analysis for 8/8 HLA-matched-unrelated donor (MUD) HCT vs. 
haploidentical HCT, 2013-2017 
Covariates N HR (95% CI) p-value 
    
Overall survival    
    Main effect    
 Haploidentical HCT 393 Reference  
 MUD HCT 1646 1.17 (0.96-1.41) 0.11 
   Remission status    
 CR1 1534 Reference  
 CR2+ 505 1.79 (1.53-2.10) < 0.001 
    Age (years)   < 0.001 
 18-29 545 Reference  
 30-39 364 1.03 (0.81-1.30) 0.82 
 40-49 391 1.38 (1.11-1.71) 0.004 
 50-59 382 1.55 (1.24-1.93) < 0.001 
 60-69 357 1.85 (1.48-2.31) < 0.001 
    Race    
 White Hispanic 223 Reference  
 White non-Hispanic 1396 0.95 (0.75-1.21) 0.68 
 Black 112 1.33 (0.94-1.87) 0.11 
 Asian 86 0.44 (0.26-0.75) 0.002 
 Other/not specified 222 1.02 (0.74-1.39) 0.92 
    HCT-CI   0.01 
 0 486 Reference  
 1 281 1.01 (0.79-1.30) 0.91 
 2 327 1.03 (0.81-1.30) 0.84 
 3+ 939 1.25 (1.04-1.50) 0.02 
     Ph chromosome/BCR-ABL1 status    
 Negative 883 Reference  
 Positive 766 0.82 (0.70-0.96) 0.02 
 T-ALL/ Unspecified subtype 390 1.03 (0.85-1.24) 0.77 
Leukemia-free survival    
    Main effect    
 Haploidentical HCT 381 Reference  
 MUD HCT 1618 1.03 (0.87-1.22) 0.73 
    Remission status    
 CR1 1509 Reference  
 CR2+ 490 1.74 (1.51-1.99) < 0.001 
    Race    
 White Hispanic 217 Reference  
 White non-Hispanic 1379 0.97 (0.78-1.19) 0.76 
 Black 105 1.33 (0.98-1.82) 0.07 
 Asian 84 0.57 (0.37-0.87) 0.010 









Covariates N HR (95% CI) p-value 
    Conditioning regimen    
 MAC-TBI 1097 Reference  
 MAC-Chemotherapy 363 1.46 (1.24-1.73) < 0.001 
 RIC/NMA 539 1.61 (1.39-1.87) < 0.001 
Non-relapse mortality    
    Main effect    
 Haploidentical HCT 381 Reference  
 MUD HCT 1618 1.42 (1.07-1.89) 0.02 
    Remission status    
 CR1 1509 Reference  
 CR2+ 490 1.33 (1.06-1.67) 0.01 
    Age (years)   < 0.001 
 18-29 539 Reference  
 30-39 356 0.86 (0.62-1.20) 0.37 
 40-49 382 1.30 (0.97-1.76) 0.08 
 50-59 372 1.61 (1.20-2.15) 0.001 
 60-69 350 1.82 (1.36-2.44) < 0.001 
    Race    
 White Hispanic 217 Reference  
 White non-Hispanic 1379 0.79 (0.58-1.09) 0.15 
 Black 105 1.04 (0.63-1.73) 0.87 
 Asian 84 0.35 (0.16-0.74) 0.006 
 Other/not specified 214 0.98 (0.66-1.47) 0.93 
Relapse    
    Main effect    
 Haploidentical HCT 381 Reference  
 MUD HCT 1618 0.83 (0.67-1.03) 0.09 
    Remission status    
 CR1 1509 Reference  
 CR2+ 490 2.20 (1.84-2.64) < 0.001 
    Gender    
 Male 1168 Reference  
 Female 831 0.81 (0.68-0.97) 0.02 
    Race    
 White Hispanic 217 Reference  
 White non-Hispanic 1379 1.04 (0.78-1.39) 0.77 
 Black 105 1.59 (1.06-2.37) 0.02 
 Asian 84 0.75 (0.44-1.26) 0.27 
 Other/not specified 214 0.88 (0.60-1.29) 0.52 
    Conditioning regimen    
 MAC-TBI 1097 Reference  
 MAC-Chemotherapy 363 1.57 (1.25-1.98) < 0.001 
 RIC/NMA 539 1.83 (1.50-2.23) < 0.001 









Covariates N HR (95% CI) p-value 
    Main effect    
 Haploidentical HCT 376 Reference  
 MUD HCT 1553 1.17 (0.98-1.41) 0.09 
    Conditioning regimen    
 MAC-TBI 1042 Reference  
 MAC-Chemotherapy 367 0.86 (0.72-1.04) 0.11 
 RIC/NMA 519 0.81 (0.68-0.95) 0.01 
Acute GVHD, Grade 3-4    
    Main effect    
 Haploidentical HCT 376 Reference  
 MUD HCT 1553 1.59 (1.15-2.20) 0.005 
    Race    
 White Hispanic 217 Reference  
 White non-Hispanic 1318 0.65 (0.47-0.90) 0.009 
 Black 109 0.90 (0.53-1.53) 0.69 
 Asian 80 0.29 (0.12-0.68) 0.005 
 Other/not specified 205 0.67 (0.43-1.06) 0.08 
Chronic GVHD    
    MUD vs. haploidentical for D/R sex match = other  1.38 (1.14-1.68) 0.001 
    MUD vs. haploidentical for D/R sex match = F/M  2.91 (1.87-4.52) < 0.001 
    Remission status    
 CR1 1528 Reference  
 CR2+ 501 0.81 (0.69-0.95) 0.009 
    D/R sex match    
 Other than F/M 1707 Reference  
 F/M 322 0.69 (0.44-1.08) 0.10 
Abbreviations: HLA, human leukocyte antigen; HCT, hematopoietic cell transplantation; N, number; HR, hazard ratio; CI, 
confidence interval; CR, complete remission; F, female; M, male; Ph, Philadelphia; BCR-ABL, breakpoint cluster region-Abelson 
murine leukemia; ALL, acute lymphoblastic leukemia; D, donor; R, recipient; CMV, cytomegalovirus; MAC, myeloablative 
conditioning; TBI, total body irradiation; RIC, reduced intensity conditioning; NMA, nonmyeloablative; GVHD, graft-versus-host 










Table 4. Multivariate analysis for 7/8 HLA-matched-unrelated donor HCT vs. 
haploidentical HCT, 2013-2017 
 
Covariates N HR (95% CI) p-value 
    
Overall survival    
    Main effect    
 Haploidentical HCT 393 Reference  
 7/8 HLA-matched UD HCT  230 1.38 (1.08-1.78) 0.01 
    Remission status    
 CR1 418 Reference  
 CR2+ 205 1.82 (1.41-2.34) < 0.001 
Leukemia-free survival    
    Main effect    
 Haploidentical HCT 381 Reference  
 7/8 HLA-matched UD 227 1.21 (0.95-1.54) 0.12 
    Remission status    
 CR1 414 Reference  
 CR2+ 194 1.84 (1.46-2.33) < 0.001 
    Race    
 White Hispanic 124 Reference  
 White non-Hispanic 277 0.95 (0.71-1.28) 0.73 
 Black 75 1.33 (0.92-1.94) 0.13 
 Asian 32 0.50 (0.25-0.97) 0.04 
 Other/not specified 100 0.70 (0.48-1.03) 0.07 
    Conditioning regimen    
 MAC-TBI 295 Reference  
 MAC-Chemotherapy 111 1.29 (0.94-1.75) 0.11 
 RIC/NMA 201 1.46 (1.12-1.89) 0.005 
Non-relapse mortality    
    Main effect    
 Haploidentical HCT 381 Reference  
 7/8 HLA-matched UD HCT 227 2.13 (1.50-3.01) < 0.001 
    Donor/recipient CMV serostatus    
 +/+ 287 Reference  
 +/- 55 0.40 (0.18-0.86) 0.02 
 -/+ 143 0.78 (0.51-1.19) 0.25 
 -/- 121 0.56 (0.34-0.92) 0.02 
Relapse    
    Main effect    
 Haploidentical HCT 381 Reference  
 7/8 HLA-matched UD HCT 227 0.81 (0.57-1.13) 0.22 
    Remission status    
 CR1 414 Reference  









Covariates N HR (95% CI) p-value 
    Race    
 White Hispanic 124 Reference  
 White non-Hispanic 277 0.94 (0.64-1.39) 0.76 
 Black 75 1.24 (0.76-2.02) 0.38 
 Asian 32 0.36 (0.14-0.93) 0.03 
 Other/not specified 100 0.58 (0.34-0.99) 0.05 
    Conditioning regimen    
 MAC-TBI 295 Reference  
 MAC-Chemotherapy 111 1.60 (1.05-2.44) 0.03 
 RIC/NMA 201 2.09 (1.49-2.95) < 0.001 
Acute GVHD, Grade 2-4    
    Main effect    
 Haploidentical HCT 376 Reference  
 7/8 HLA-matched UD HCT  216 1.33 (1.02-1.73) 0.04 
    Conditioning regimen    
 MAC-TBI 288 Reference  
 MAC-Chemotherapy  107 0.68 (0.47-0.98) 0.04 
 RIC/NMA 196 0.68 (0.51-0.92) 0.01 
Acute GVHD, Grade 3-4    
    Main effect    
 Haploidentical HCT 376 Reference  
 7/8 HLA-matched UD HCT 216 1.86 (1.23-2.80) 0.003 
Chronic GVHD    
    Main effect    
 Haploidentical HCT 393 Reference  
 7/8 HLA-matched UD HCT  230 1.72 (1.34-2.20) < 0.001 
Abbreviations: HLA, human leukocyte antigen; HCT, hematopoietic cell transplantation; N, number; HR, hazard ratio; CI, 
confidence interval; CR, complete remission; F, female; M, male; Ph, Philadelphia; BCR-ABL, breakpoint cluster region-Abelson 
murine leukemia; ALL, acute lymphoblastic leukemia; D, donor; R, recipient; CMV, cytomegalovirus; MAC, myeloablative 
conditioning; TBI, total body irradiation; RIC, reduced intensity conditioning; NMA, nonmyeloablative; GVHD, graft-versus-host 










Table 5. Multivariate analysis for umbilical cord blood (UCB) HCT vs. haploidentical 
HCT, 2013-2017 
 
Covariates N HR (95% CI) p-value 
    
Overall survival    
    UCB HCT vs. haploidentical HCT <=18 months  1.93 (1.45-2.56) < 0.001 
    UCB HCT vs. haploidentical HCT >18 months  0.68 (0.38-1.21) 0.19 
    Remission status    
 CR1 481 Reference  
 CR2+ 217 1.62 (1.27-2.07) < 0.001 
    Karnofsky score    
 <90% 259 Reference  
 >=90% 429 0.81 (0.64-1.04) 0.10 
    Conditioning regimen    
 MAC-TBI 380 Reference  
 MAC-Chemotherapy 74 2.14 (1.45-3.14) < 0.001 
 RIC/NMA 243 1.22 (0.93-1.59) 0.15 
Leukemia-free survival     
    UCB HCT vs. haploidentical HCT <=18 months  1.40 (1.09-1.79) 0.007 
    UCB HCT vs. haploidentical HCT  >18 months  0.58 (0.31-1.07) 0.08 
    Remission status    
 CR1 469 Reference  
 CR2+ 203 1.59 (1.27-1.99) < 0.001 
    Race    
 White Hispanic 144 Reference  
 White non-Hispanic 310 0.86 (0.65-1.13) 0.27 
 Black 83 1.33 (0.93-1.89) 0.12 
 Asian 41 0.55 (0.31-0.97) 0.04 
 Other/not specified 94 0.94 (0.65-1.36) 0.74 
    Conditioning regimen    
 MAC-TBI 364 Reference  
 MAC-Chemotherapy 72 1.77 (1.23-2.55) 0.002 
 RIC/NMA 235 1.51 (1.19-1.91) < 0.001 
Non-relapse mortality    
    Main effect    
 Haploidentical HCT 381 Reference  
 UCB HCT 291 2.08 (1.45-2.99) < 0.001 
    Karnofsky score    
 <90% 247 Reference  
 >=90% 416 0.65 (0.46-0.90) 0.01 
    Conditioning regimen    
 MAC-TBI 364 Reference  
 MAC-Chemotherapy 72 1.96 (1.16-3.32) 0.01 









Covariates N HR (95% CI) p-value 
Relapse    
    Main effect    
 Haploidentical HCT 381 Reference  
 UCB HCT 291 0.83 (0.60-1.13) 0.23 
    Remission status    
 CR1 469 Reference  
 CR2+ 203 1.88 (1.40-2.53) < 0.001 
    Race    
 White Hispanic 144 Reference  
 White non-Hispanic 310 0.99 (0.68-1.45) 0.98 
 Black 83 1.51 (0.95-2.39) 0.08 
 Asian 41 0.55 (0.26-1.19) 0.13 
 Other/not specified 94 0.73 (0.43-1.25) 0.25 
    Conditioning regimen    
 MAC-TBI 364 Reference  
 MAC-Chemotherapy 72 1.64 (0.99-2.71) 0.05 
 RIC/NMA 235 2.01 (1.47-2.74) < 0.001 
Acute GVHD, Grade 2-4    
    Main effect    
 Haploidentical HCT 376 Reference  
 UCB HCT 285 1.83 (1.46-2.30) < 0.001 
Acute GVHD, Grade 3-4    
    Main effect    
 Haploidentical HCT 376 Reference  
 UCB HCT 285 1.97 (1.35-2.88) < 0.001 
Chronic GVHD    
    Main effect    
 Haploidentical HCT 393 Reference  
 UCB HCT 297 1.13 (0.86-1.47) 0.38 
    Conditioning regimen    
 MAC-TBI 375 Reference  
 MAC-Chemotherapy 71 1.11 (0.72-1.72) 0.64 
 RIC/NMA 243 0.65 (0.49-0.87) 0.003 
    HCT-CI   0.05 
 0 169 Reference  
 1 98 0.60 (0.39-0.92) 0.02 
 2 105 0.91 (0.63-1.31) 0.60 
 3+ 317 0.68 (0.50-0.91) 0.01 
    
Abbreviations: HLA, human leukocyte antigen; HCT, hematopoietic cell transplantation; N, number; HR, hazard ratio; CI, 
confidence interval; CR, complete remission; F, female; M, male; Ph, Philadelphia; BCR-ABL, breakpoint cluster region-Abelson 
murine leukemia; ALL, acute lymphoblastic leukemia; D, donor; R, recipient; CMV, cytomegalovirus; MAC, myeloablative 
conditioning; TBI, total body irradiation; RIC, reduced intensity conditioning; NMA, nonmyeloablative; GVHD, graft-versus-











Table 6. Causes of death by cohort  
 
Characteristic Haploidentical MSD MUD 7/8 UD UCB 
      
Number of deaths 132 564 625 103 130 
Cause of death      
Acute lymphoblastic leukemia 64 (48) 293 (52) 240 (38) 33 (32) 40 (31) 
Graft failure 1 (<1) 4 (<1) 1 (<1) 3 (3) 3 (2) 
Graft-versus-host disease 7 (5) 81 (14) 126 (20) 25 (24) 16 (12) 
Infection 28 (21) 98 (17) 126 (20) 21 (20) 30 (23) 
Idiopathic pneumonia 4 (3) 5 (<1) 7 (1) 0 5 (4) 
Acute respiratory distress syndrome 3 (2) 7 (1) 9 (1) 0 4 (3) 
Organ failure 8 (6) 31 (5) 53 (8) 9 (9) 19 (15) 
Organ toxicity 0 4 (<1) 1 (<1) 2 (2) 0 
Secondary malignancy 2 (2) 4 (<1) 4 (<1) 2 (2) 2 (2) 
Hemorrhage 3 (2) 4 (<1) 4 (<1) 1 (<1) 2 (2) 
Accident/suicide 0 0 3 (<1) 0 0 
Vascular 0 2 (<1) 1 (<1) 0 2 (2) 
Other known 11 (8) 23 (4) 39 (6) 7 (7) 6 (5) 
Unknown 1 (<1) 8 (1) 11 (2) 0 1 (<1) 
      
Abbreviations: MSD, matched sibling donor; MUD, matched unrelated donor; 7/8 UD, 7/8 HLA-matched unrelated donor; UCB, 




































































































HR	0.99	(0.81-1.21),	P=0.93	 HR	0.83	(0.67-1.03),	P=0.09	 HR	0.81	(0.57-1.13),	P=0.22	 HR	0.83	(0.60-1.13),	P=0.23	










 http://ashpublications.org/bloodadvances/article-pdf/doi/10.1182/bloodadvances.2021004916/1823558/bloodadvances.2021004916.pdf by guest on 23 Septem
ber 2021
